REDEFINE 1: CagriSema improves blood pressure and body composition
Introduction Obesity is a complex, multifactorial disease closely linked to cardiovascular comorbidities such as high blood pressure. In this context, drug treatment plays a central role in achieving sustained weight loss and metabolic improvements. During Obesity Week 2025, the results of the REDEFINE 1 study were presented, a phase 3a, double-blind, controlled trial that evaluated […]
GLP-1: key adherence to maintaining weight loss
Introduction Sustained adherence to GLP-1 receptor agonists has become one of the main challenges in the treatment of obesity and type 2 diabetes.A real-world analysis presented at ObesityWeek 2025 revealed that discontinuing these therapies leads to significant weight regain, particularly in patients without diabetes, underscoring the importance of therapeutic persistence in maintaining long-term benefits. Study […]
Semaglutide: Treat-to-Target approach improves cardiovascular profile
Introduction Recent advances in pharmacotherapy for obesity have shown that the magnitude of weight loss is not the only relevant goal. At ObesityWeek 2025, results were presented from the secondary analysis of the STEP UP study, which evaluated the application of a “treat-to-target” (TTT) treatment strategy with semaglutide, aimed at achieving specific low cardiometabolic risk […]
Tirzepatide improves quality of life more than semaglutide
Taldefgrobep: TGF-β inhibitor with anti-obesity effect
